What is the clinical evidence from this study?

Study design: Observational. Population: Significant mitral stenosis (n=189). Intervention: Percutaneous transseptal mitral valvotomy (PTMV). Primary outcome: Clinical improvement of at least one NYHA functional class.

What question did this study set out to answer?

To evaluate procedural success, safety, and short- to medium-term clinical outcomes in patients undergoing percutaneous transseptal mitral valvotomy for significant mitral stenosis.

December 1, 1998Australian and New Zealand Journal of Medicine

Percutaneous transseptal mitral valvotomy‐progress report

View Full Paper

Ask AI

Bookmark

Key result

Percutaneous transseptal mitral valvotomy achieved clinical improvement of at least one NYHA class in 91% of patients and decreased mean mitral valve gradient from 11.5 to 4.9 mmHg.

Why the study?

Does percutaneous transseptal mitral valvotomy improve hemodynamics and clinical symptoms in patients with significant mitral stenosis?

Population

189 patients with significant mitral stenosis, mean age 53.5 years, 156 females and 33 males. Six patients…

Design

Case_series

Follow-up

Short and medium term (up to 67 months)

Authors

RMR. M. McCredieSingapore General Hospital AHAdam T. HillCentre for Inflammation Research RAR. Marshall AllanThe University of Melbourne

Discussion

Member takes

Implication

May support symptom relief in mitral stenosis; leaves open efficacy confirmation in randomized trials before practice change.

Key Points

To evaluate procedural success, safety, and short- to medium-term clinical outcomes in patients undergoing percutaneous transseptal mitral valvotomy for significant mitral stenosis.
Retrospective review of 200 attempted percutaneous transseptal mitral valvotomy (PTMV) procedures performed in 189 patients (156 female, 33 male; mean age 53.5 years; 6 pregnant) between May 1988 and May 1994.
Hemodynamic measurements, functional class improvement, and procedural complications were assessed during short- and medium-term follow-up.
Initial valve split succeeded in 183/189 procedures (97%), with 91% (172/189) improving by at least one NYHA functional class.
Mean mitral valve gradient decreased from 11.5 ± 5.1 to 4.9 ± 4.1 mmHg, mean cardiac output rose from 3.9 ± 1.1 to 4.4 ± 1.4 L/min, and mean valve area expanded from 1.0 ± 0.3 to 2.1 ± 0.9 cm².
Complications included severe mitral incompetence requiring valve replacement in 10 patients, 2 transient cerebral embolic events, 42 small asymptomatic atrial septal defects, zero early deaths, and 20 repeat PTMV procedures for re-stenosis.

Study Design

Type

Observational (n=189)

Structured PICO

Does percutaneous transseptal mitral valvotomy improve hemodynamics and clinical symptoms in patients with significant mitral stenosis?

Population

189 patients (mean age 53.5 years, 82.5% female) with significant mitral stenosis undergoing percutaneous transseptal mitral valvotomy.

Exposure

Percutaneous transseptal mitral valvotomy (PTMV)

Outcome

Procedural success (valve split), clinical improvement (NYHA functional class), and hemodynamic changes (mitral valve gradient, cardiac output, mitral valve area)surrogate

Percutaneous transseptal mitral valvotomy provides significant hemodynamic and clinical improvement with low risk, establishing it as an effective alternative to surgery for mitral stenosis.

Cite This Study

McCredie et al. (1998) conducted an observational in Significant mitral stenosis (n=189). Percutaneous transseptal mitral valvotomy (PTMV) was evaluated on Clinical improvement of at least one NYHA functional class. Percutaneous transseptal mitral valvotomy achieved clinical improvement of at least one NYHA class in 91% of patients and decreased mean mitral valve gradient from 11.5 to 4.9 mmHg.

synapsesocial.com/papers/6a9de6fa67d34f09a3f9a0a8 https://doi.org/10.1111/j.1445-5994.1998.tb01558.x

Topics

Echocardiography

View Full Paper

Ask AI

Bookmark

December 1, 1998Australian and New Zealand Journal of Medicine

Percutaneous transseptal mitral valvotomy‐progress report

View Full Paper

Ask AI

Bookmark

Key result

Percutaneous transseptal mitral valvotomy achieved clinical improvement of at least one NYHA class in 91% of patients and decreased mean mitral valve gradient from 11.5 to 4.9 mmHg.

Why the study?

Does percutaneous transseptal mitral valvotomy improve hemodynamics and clinical symptoms in patients with significant mitral stenosis?

Population

189 patients with significant mitral stenosis, mean age 53.5 years, 156 females and 33 males. Six patients…

Design

Case_series

Follow-up

Short and medium term (up to 67 months)

Authors

RMR. M. McCredieSingapore General Hospital AHAdam T. HillCentre for Inflammation Research RAR. Marshall AllanThe University of Melbourne

Discussion

Member takes

Implication

May support symptom relief in mitral stenosis; leaves open efficacy confirmation in randomized trials before practice change.

Key Points

To evaluate procedural success, safety, and short- to medium-term clinical outcomes in patients undergoing percutaneous transseptal mitral valvotomy for significant mitral stenosis.
Retrospective review of 200 attempted percutaneous transseptal mitral valvotomy (PTMV) procedures performed in 189 patients (156 female, 33 male; mean age 53.5 years; 6 pregnant) between May 1988 and May 1994.
Hemodynamic measurements, functional class improvement, and procedural complications were assessed during short- and medium-term follow-up.
Initial valve split succeeded in 183/189 procedures (97%), with 91% (172/189) improving by at least one NYHA functional class.
Mean mitral valve gradient decreased from 11.5 ± 5.1 to 4.9 ± 4.1 mmHg, mean cardiac output rose from 3.9 ± 1.1 to 4.4 ± 1.4 L/min, and mean valve area expanded from 1.0 ± 0.3 to 2.1 ± 0.9 cm².
Complications included severe mitral incompetence requiring valve replacement in 10 patients, 2 transient cerebral embolic events, 42 small asymptomatic atrial septal defects, zero early deaths, and 20 repeat PTMV procedures for re-stenosis.

Study Design

Type

Observational (n=189)

Structured PICO

Does percutaneous transseptal mitral valvotomy improve hemodynamics and clinical symptoms in patients with significant mitral stenosis?

Population

189 patients (mean age 53.5 years, 82.5% female) with significant mitral stenosis undergoing percutaneous transseptal mitral valvotomy.

Exposure

Percutaneous transseptal mitral valvotomy (PTMV)

Outcome

Procedural success (valve split), clinical improvement (NYHA functional class), and hemodynamic changes (mitral valve gradient, cardiac output, mitral valve area)surrogate

Percutaneous transseptal mitral valvotomy provides significant hemodynamic and clinical improvement with low risk, establishing it as an effective alternative to surgery for mitral stenosis.

Cite This Study

synapsesocial.com/papers/6a9de6fa67d34f09a3f9a0a8 https://doi.org/10.1111/j.1445-5994.1998.tb01558.x

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Echocardiography

View Full Paper

Ask AI

Bookmark